Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal
Novo Holdings, the parent company of Novo Nordisk, can proceed with its planned $16.5 billion acquisition of Catalent, a leading contract drug manufacturer, after U.S.